Argenx : Positive phase II results in Sjögren’s disease
>Phase II results support a move to phase III - Argenx announced positive results for the phase II RHO study evaluating efgartigimod in patients suffering from Sjögren’s disease (SjD). The company has not announced any figures for the results at this stage since they will be presented at an upcoming medical conference. Based on these results, the company envisages continuing the development of efgartigimod in phase III, which could lead to a commercial launch in this ...Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.